Remdesivir and Graft Loss in Kidney Transplant Recipients With Symptomatic COVID-19

Дата публикации: 28-07-2026 00:00:00

This cohort study emulating a target trial estimates risk of 1-year all-cause graft loss in adult kidney transplant recipients with symptomatic COVID-19 who received remdesivir within 7 days of diagnosis vs those who did not.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Pharmacokinetics, lineage identity, and trafficking of ex vivo expanded polyclonal regulatory T cells in a prospective randomized clinical trial of kidney transplant recipients with allograft inflammation	0	9.14	27-08-2026
2	Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease	0	8.74	28-07-2026
3	Myelodysplastic syndrome after COVID-19 infection in a living-donor kidney transplant recipient: a case report and literature review	0	17.47	10-08-2026
4	Nearly half of kidney transplant patients never even get started	0	6.69	01-07-2026
5	Accessibility of Publicly Posted Kidney Transplant Waitlist Criteria Under IOTA	0	6.27	19-10-2026
6	RAFT-OS Transplant for Aniridia-Related Keratopathy	0	19.17	23-07-2026
7	Kidney transplant, wait-list rates lower with Medicare Advantage	0	10.32	08-10-2026
8	The accuracy of procalcitonin in detecting non-viral infections in liver transplant recipients following orthotopic liver transplantation: A single center experience	0	5	16-07-2026
9	Reuters: применение "Ремдесивира" может сократить сроки лечения COVID-19 на пять суток	0	0	08-10-2020
10	SGLT2 Inhibitors for Prevention of AKI	0	16.3	30-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.68. Источник: jamanetwork.com.